Asciminib is named as an intervention in 3 current clinical trials in our USA, UK, India and China registers. None are recruiting at the moment. The most common phase is Phase 3. The lead sponsor is Novartis Pharmaceuticals. The most-studied condition is Philadelphia Chromosome-Positive Chronic Myeloid Leukemia.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
NCT04971226 · ClinicalTrials.gov ↗ · Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
|
Phase 3 | Active, closed | Novartis Pharmaceuticals | UK, USA, India, China |
|
A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)
NCT05456191 · ClinicalTrials.gov ↗ · Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
|
Phase 3 | Active, closed | Novartis Pharmaceuticals | UK, USA, India |
|
Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia
NCT05384587 · Chronic Myelogenous Leukemia - Chronic Phase
|
Phase 2 | Active, closed | Novartis Pharmaceuticals | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Novartis Pharmaceuticals | 3 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 3 | 0 |
| Clinical trials in UK | 2 | 0 |
| Clinical trials in India | 2 | 0 |
| Clinical trials in China | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our USA, UK, India and China registers name Asciminib as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Not at the moment. None of the 3 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
The lead sponsor is Novartis Pharmaceuticals. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Asciminib works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Asciminib works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Asciminib (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.